The Drugs and Cosmetics Act of 1940 and its subsequent amendments aim to regulate and ensure safety and quality of drugs and cosmetics in India. Key provisions include licensing requirements for import, manufacture, and sale of drugs and cosmetics. The act establishes regulatory bodies like the Drugs Technical Advisory Board and Drugs Control Committees. It defines terms like misbranded, adulterated, and spurious drugs and cosmetics. The schedules to the act and rules classify drugs based on their use and safety.
This presentation contains basics of Drugs & Cosmetics Act. All the legal definitions, objective and various schedules belonging to the act are mentioned. This is the first part of Drugs & Cosmetics Act, other parts of the acts will be described in the next presentations.
Objectives of the Drugs and Cosmetics Act
Definitions
DRUGS TECHNICAL ADVISORY BOARD (DTAB)
GOVERNMENT ANALYST
Drug Inspectors
Regulatory provisions relating to import of cosmetics
Offences & penalties
Loan license
Requirements pertaining to labeling of cosmetics
References
The Drugs and Cosmetics Act, 1940 is an Act of the Parliament of India which regulates the import, manufacture and distribution of drugs in India. The primary objective of the act is to ensure that the drugs and cosmetics sold in India are safe, effective and conform to state quality standards.
This presentation contains basics of Drugs & Cosmetics Act. All the legal definitions, objective and various schedules belonging to the act are mentioned. This is the first part of Drugs & Cosmetics Act, other parts of the acts will be described in the next presentations.
Objectives of the Drugs and Cosmetics Act
Definitions
DRUGS TECHNICAL ADVISORY BOARD (DTAB)
GOVERNMENT ANALYST
Drug Inspectors
Regulatory provisions relating to import of cosmetics
Offences & penalties
Loan license
Requirements pertaining to labeling of cosmetics
References
The Drugs and Cosmetics Act, 1940 is an Act of the Parliament of India which regulates the import, manufacture and distribution of drugs in India. The primary objective of the act is to ensure that the drugs and cosmetics sold in India are safe, effective and conform to state quality standards.
DRUG AND COSMETIC ACT -
For more information regarding PHARMACOVIGILANCE, CLINICAL RESEARCH, CLINICAL DATA MANAGEMENT & DRUG REGULATORY AFFAIRS kindly contact us on 9028839789
Narcotic and Psychotropic Substance act 1985Prakash Mali
The statutory control over narcotic drugs was being exercised under The Opium Act, 1857, The Opium Act, 1878 and The Dangerous Drugs Act, 1930.
India had no legislation regarding narcotics until 1985. Cannabis smoking in India has been known since at least 2000 BC and is first mentioned in the Atharvaveda, which dates back a few hundred years BC.
The poison Act, 1919 was passed on 3rd September , 1919, with a view to control the import, possession and sale of Poisons.
It extends to whole of India but is not applicable to the state J&K.
The Act of 1919 replaced the poison Act of 1904.
The term “Poison” has not been defined under the Act.
Under the Act, the central Govt. has been authorised to regulate the import of poison across, while the various State Govt. has been authorised to make rules regarding the possession and sale of poison within their respective territories.
History and Objectives
Definitions
Administration of the act and rules
Provisions related to Import
Provisions related to Manufacture
Provisions related to Sale
Labeling and Packaging
Schedules to the act and rules
Recent amendment act, 2008
List of forms
Narcotic Drugs and Psychotropic Substances Act, 1985Ganesh Shevalkar
The Narcotic Drugs and Psychotropic Substances Act, 1985, commonly referred to as the NDPS Act, is an Act of the Parliament of India that prohibits a person to produce/manufacture/cultivate, possess, sell, purchase, transport, store, and/or consume any narcotic drug or psychotropic substance.
Drugs and Cosmetics Act 1940 and Rules 1945 - Detailed reviewMd Altamash Ahmad
OBJECTIVES
• To prevent substandard in drugs, presumably for treatment, maintaining high standards of medical
• To regulate the import, manufacture, distribution and sale of drugs & cosmetics through licensing.
• Manufacture, distribution and sale of drugs and cosmetics by qualified persons only.
• Act has nothing to do with the Excise duty
• To regulate the manufacture and sale of Ayurvedic, Siddha and Unani drugs.
• To establish Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committees (DCC) for Allopathic and allied drugs and cosmetics.
A presentation aimed at providing information with regards to the Pharmacy Act, 1948.
-INTRODUCTION
-HISTORY OF THE ACT
-PHARMACY COUNCIL OF INDIA
-STATE PHARMACY COUNCIL
-SPECIAL PROVISIONS OF THE ACT
-OFFENCES AND PENALTIES
-CONCLUSION
-REFERENCES
DRUG AND COSMETIC ACT -
For more information regarding PHARMACOVIGILANCE, CLINICAL RESEARCH, CLINICAL DATA MANAGEMENT & DRUG REGULATORY AFFAIRS kindly contact us on 9028839789
Narcotic and Psychotropic Substance act 1985Prakash Mali
The statutory control over narcotic drugs was being exercised under The Opium Act, 1857, The Opium Act, 1878 and The Dangerous Drugs Act, 1930.
India had no legislation regarding narcotics until 1985. Cannabis smoking in India has been known since at least 2000 BC and is first mentioned in the Atharvaveda, which dates back a few hundred years BC.
The poison Act, 1919 was passed on 3rd September , 1919, with a view to control the import, possession and sale of Poisons.
It extends to whole of India but is not applicable to the state J&K.
The Act of 1919 replaced the poison Act of 1904.
The term “Poison” has not been defined under the Act.
Under the Act, the central Govt. has been authorised to regulate the import of poison across, while the various State Govt. has been authorised to make rules regarding the possession and sale of poison within their respective territories.
History and Objectives
Definitions
Administration of the act and rules
Provisions related to Import
Provisions related to Manufacture
Provisions related to Sale
Labeling and Packaging
Schedules to the act and rules
Recent amendment act, 2008
List of forms
Narcotic Drugs and Psychotropic Substances Act, 1985Ganesh Shevalkar
The Narcotic Drugs and Psychotropic Substances Act, 1985, commonly referred to as the NDPS Act, is an Act of the Parliament of India that prohibits a person to produce/manufacture/cultivate, possess, sell, purchase, transport, store, and/or consume any narcotic drug or psychotropic substance.
Drugs and Cosmetics Act 1940 and Rules 1945 - Detailed reviewMd Altamash Ahmad
OBJECTIVES
• To prevent substandard in drugs, presumably for treatment, maintaining high standards of medical
• To regulate the import, manufacture, distribution and sale of drugs & cosmetics through licensing.
• Manufacture, distribution and sale of drugs and cosmetics by qualified persons only.
• Act has nothing to do with the Excise duty
• To regulate the manufacture and sale of Ayurvedic, Siddha and Unani drugs.
• To establish Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committees (DCC) for Allopathic and allied drugs and cosmetics.
A presentation aimed at providing information with regards to the Pharmacy Act, 1948.
-INTRODUCTION
-HISTORY OF THE ACT
-PHARMACY COUNCIL OF INDIA
-STATE PHARMACY COUNCIL
-SPECIAL PROVISIONS OF THE ACT
-OFFENCES AND PENALTIES
-CONCLUSION
-REFERENCES
Drugs and Cosmatic Act,1940 and its rules 1945TameshSonkar
Objectives, Definitions, Legal definitions of schedules to the Act and Rules
Import of drugs Classes of drugs and cosmetics prohibited from import
,Import under license or permit. Offences and penalties.
Manufacture of drugs Prohibition of manufacture and sale of certain drugs
Conditions for grant of license and conditions of license for manufacture of
drugs, Manufacture of drugs for test, examination and analysis
,manufacture of new drug, loan license and repacking license.
Drugs and Cosmetics Act, 1940 and its rules 1945:
Objectives, Definitions, Legal definitions of schedules to the Act and
Rules
Import of drugs – Classes of drugs and cosmetics prohibited from import, Import under
license or permit. Offences and penalties.
Manufacture of drugs – Prohibition of manufacture and sale of certain drugs,
Conditions for grant of license and conditions of license for manufacture of drugs,
Manufacture of drugs for test, examination and analysis, manufacture of new drug, loan
license and repacking license.
Drugs and Cosmetics Act, 1940 and its rules 1945:
Objectives, Definitions, Legal definitions of schedules to the Act and
Rules
Import of drugs – Classes of drugs and cosmetics prohibited from import, Import under
license or permit. Offences and penalties.
Manufacture of drugs – Prohibition of manufacture and sale of certain drugs,
Conditions for grant of license and conditions of license for manufacture of drugs,
Manufacture of drugs for test, examination and analysis, manufacture of new drug, loan
license and repacking license.
Drugs and Cosmetics Act 1940 and Rules 1945 - Objectives, Legal definitionMd Altamash Ahmad
Drugs and Cosmetics Act, 1940 was introduced by Government of India to regulate the import, manufacture, distribution and sale of drugs and cosmetics in India. This act can be considered as landmark in the history of drug legislation in India. It is Act no. 23 of 1940 and was introduced on 5th April, 1940 and enacted on 10th April, 1940.
Introduction & Objectives
Schedules of the Act.
Schedules of the Rule
Definitions
Administrative bodies
Import & Registration.
Manufacture of drugs
Sale of drugs
Labeling & packaging of drugs
Conditions for grant of licenses
Detailed study of schedules g, h, M, N, P, T, U,V, X & Y
Drug & Cosmetic ACT 1940 & Rules 1945 unit I.pptxGayatriBahatkar1
Objectives, Definitions, Legal definitions of schedules to the Act and
Rules
Import of drugs – Classes of drugs and cosmetics prohibited from import, Import under
license or permit. Offences and penalties.
Manufacture of drugs – Prohibition of manufacture and sale of certain drugs,
Conditions for grant of license and conditions of license for manufacture of drugs,
Manufacture of drugs for test, examination and analysis, manufacture of new drug, loan
license and repacking license.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
3. •The act was prepared in accordance to the recommendations of the
Chopra Committee formed in 1930.
•British misrule-Providing poor healthcare system to Indian
citizens, Observations made by-Drugs Enquiry Committee,
Indian MedicalAssociation
•Reports in- Indian Medical Gazette during 1920-30
•1940 – Drugs and CosmeticsAct
• The related Drugs Rules was passed in 1945
•Since 1940, the act has undergone several amendments and is now
known as the Drugs and Cosmetics Act, 1940
4. The primary objective of the act is to ensure that the drugs and
cosmetics sold in India are safe, effective and conform to state
quality standards.
To regulate the import, manufacture, distribution and sale of drugs
and cosmetics through licensing.
To provide guidelines for the storage, sale, display and prescription
of each schedule
Manufacture , distribution and sale of drugs and cosmetics by
qualified persons only.
To establish Drugs Consultative Committees(DCC).
5. •Drug- as defined in the act includes a wide variety of substance,
diagnostic and medical devices.
•Cosmetic- as any product that is meant to be applied to the human
body for the purpose of beautifying or cleansing. The definition
however excludes soaps. In 1964, the act was amended to
include Ayurveda and Unani drugs.
6. Adulterated Drug-Section 27 deals fake and adulterated drugs. The act
requires that ingredients of the drugs should be printed on the label
• It consists, in whole or in part, of any filthy, putrid or decomposed
substance; or
• If it has been prepared, packed or stored under insanitary conditions
whereby it may have been contaminated with filth or whereby it may
have been rendered injurious to health; or
• If its container is composed in whole or in part, of any poisonous or
deleterious substance which may render the contents injurious to health
Spurious drugs.
(a) if it is imported under a name which belongs to another drug; or
(b) if it is an imitation of, or a substitute for, another drug or resembles
another drug in a manner likely to deceive or bears upon it or upon its
label or container the name of another drug unless it is plainly and
conspicuously marked so as to reveal its true character and its lack of
identity with such other drug; or
7. (c) if the label or the container bears the name of an individual
or company purporting to be the manufacturer of the drug,
which individual or company is fictitious or does not exist; or
Misbranded cosmetics —
(a) if it contains a color which is not prescribed; or
(b) if it is not labeled in a prescribed manner; or
(c) if the label or container or anything accompanying the
cosmetic bears any statement which is false or misleading in
any particular
8. Spurious cosmetics.—
(a) if it is imported under the name which belongs to another cosmetic;
or
(b) if it is an imitation of, or is a substitute for, another cosmetic or
resembles another cosmetic in a manner likely to deceive or bears upon
it or upon its label or container the name of another cosmetic, unless it is
plainly or
conspicuously marked so as to reveal its true character and its lack of
identity with such other cosmetic; or
(c) if the label or the container bears the name of an individual or
company purporting to be the manufacturer
of the cosmetic, which individual or company is fictitious or does not
exist; or
(d) if it purports to be the product of a manufacturer of whom it is not
truly a product.
9. A) Advisory :
1)Drugs Technical Advisory Board-DTAB
2)Drugs Consultative Committee-DCC
B) Analytical :
1)Central Drugs Laboratory - CDL
2)Drug Control Laboratory in states
3)Government Analysts
C) Executives :
1)Licensing authorities
2)Controlling authorities
3)Drug Inspectors
10. (i) the Director General of Health Services, who shall be Chairman;
(ii) the Drugs Controller, India
(iii) the Director of the Central Drugs Laboratory, Calcutta
(iv) the Director of the Central Research Institute, Kasauli
(v) the Director of Indian Veterinary Research Institute, Izatnagar
(vi) the President of Medical Council of India
(vii) the President of the Pharmacy Council of India
(viii) the Director of Central Drug Research Institute, Lucknow
(ix) two persons to be nominated by the Central Government from
among persons who are in charge of drugs control in the States
11. 1) Two persons by the Central Government
2) One person by the Central Government from the pharmaceutical
industry
3) Two persons holding the appointment of Government Analyst
under this Act
12. -one person to be nominated by the Central Government from the
pharmaceutical industry;
-one pharmacologist to be elected by the Governing Body of the Indian
Council of Medical Research;
-one person to be elected by the Central Council of the Indian Medical
Association;
-one person to be elected by the Council of the Indian Pharmaceutical
Association;
The nominated and elected members of the Board shall hold office for
three years, but shall be eligible for renomination and re-election
Functions
•To advise the Central Government and the State Governments on
technical matters
•To carry out the other functions assigned to it by this Act
13. The Central Government shall, as soon as may be, established a
Central Drugs Laboratory under the control of a Director to be
appointed by the Central Government, to carry out the functions
entrusted to it by this Act .
-It is also an advisory body constituted by central government.
-Constitution: Two representatives of the Central Government & One
representative of each State Government
14. -To advise the Central Government, the State Governments and the
Drugs Technical Advisory Board on any other matter tending to secure
uniformity throughout India in the administration of this Act.
-The Drugs Consultative Committee shall meet when required
- Has power to regulate its own procedure.
15. (1) The Central Government may constitute an advisory committee to be
called “the Drugs Consultative Committee” to advise the Central
Government, the State Governments and the Drugs Technical Advisory
Board on any other matter tending to secure uniformity throughout
[India] in the administration of this Act.
(2) The Drugs Consultative Committee shall consist of two
representatives of the Central Government to be nominated by that
Government and one representative of each State Government to be
nominated by the State Government concerned.
(3) The Drugs Consultative Committee shall meet when required to do so
by the Central Government and shall have power to regulate its own
procedure.
16. -Testing of drug sample
-Analysis of food sample
-Analysis of excise sample
17. Duties:
• Analyze or tested such sample or drugs and cosmetics may be
sent to him by Inspectors
• Timely forward reports to the Government giving the results
of analytics work.
18. Duties:
• To inspect all establishments licensed for the sale of drugs within the
area assigned to him
• To send for test or analysis.
•To investigate any complaint.
•To maintain a record of all inspections made by him.
• To maintain a record of action taking by him in the performance of his
duties.
19. Function:
1. Inspection of all area where the drug and cosmetics are
being manufactured/sold/stocked
2. Take sample of any drug and cosmetic are being
manufactured/sold/stocked
21. IMPORTofdrugs
Classes of drugs prohibited to import
Import of drug under license
1)Specified in Schedule-C/C1
2)Specified in Schedule-X
3)Imported forTest/Analysis
4)Imported for personal use
5)Any new drugs
Drugs exempted from provisions of import
Offences and Penalties
22. Classesof drugsprohibitedto
import
Misbranded drugs
Drugs of substandard quality
Drugs claiming to cure diseases specified in Sch-J
Adulterated drugs
Spurious drugs
Drugs whose manufacture, sale/distribution are
prohibited in original country, except for the purpose
of test, examination and analysis.
Patent/Proprietary medicines whose true formula is
not disclosed.
23. Import of drugswithoutlicense
Substances not used for medicinal pupose
Drugs in Sch-C1 required for manufacturing and not for
medicinal use.
Substances which are both drugs and foods such as:
Condensed/Powdered Milk
Malt
Lactose
Farex/Cereal
Oats
Predigested foods
Ginger, Pepper, Cumin, Cinnamon
25. • From the date notified by the State Government, no person shall himself
manufacture for sale or distribution or sell or distribute-
o Any drug which is not of standard quality or is misbranded, adulterated
or spurious;
o Any cosmetic which not of standard quality or is misbranded,
adulterated or spurious;
o Any patent or proprietary medicine whose formulae is not disclosed on
label or the container;
o Any drug which purports to cure, mitigate or prevent any disease
specified in Schedule J;
o Any cosmetic containing any ingredient which may render it unsafe or
harmful for use;
o Any drug or cosmetic in contravention of this act or rules there under;
o Any drug or cosmetic which has been imported or manufactured in
contravention of the provisions of this Act or Rules there under or in
contravention of the conditions of a license.
26. Schedulesto theact
underFirst schedule – Names of books
Ayurvedic and Siddha systems
Second schedule – Standard to be complied
with by imported drugs and by drugs
manufactured for sale, sold, stocked or exhibited
for sale or distribution
27. Schedulesto therules
SJTPC 27
TYPE CONTENT
“A” Performa for forms( Application, issue, renewal, etc.)
“B” Rates of fee for test or analysis by CDL or Govt. analysts
“C” List of Biological and special products (Injectable) applicable
to specialprovisions.
“C1” List of Biological and special products (nonparenteral)
applicable tospecial provisions.
“D” List of drugs that are exempted from provisions of import
“E1” List of poisonous substances under the Ayurvedic , Siddha and
Unani systems
“F” Provisions applicable to blood bank
28. Schedulesto therules
TYPE CONTENT
“F1” Special provision applicable to biological and special products, eg.
Bacterial and viral vaccines, sera from living animals, bacterial
origin diagnosticagents
“F2” Standards for surgicaldressings
“F3” Standards for umbilicaltapes
“FF” Standards for ophthalmicpreparations
“G” List of substances required to be used under medical
supervision andlabelled accordingly
“H” List of substances (prescription) that should be sold by retail only
on prescriptionsof R.M.P.
29. Schedulesto therules
TYPE CONTENT
“J” List of diseases and ailments that drug should not claim to cure
“K” List of drugs that are exempted from certain provisions regarding
manufacture
“M” Requirements of manufacturing premises, GMP requirements of factory
premises, plants andequipments
“M1” Requirements of factory premises for manufacture of Homeopathic
medicines
“M2” Requirements of factory premises for manufacture of cosmetics
“M3” Requirements of factory premises for manufacture of medical devices
“N” List of equipment to run a Pharmacy
“O” Standards for disinfectant fluids
30. TYPE CONTENT
“P” Life period(expiry) ofdrugs
“Q” Coal tar colors permitted to be used in cosmetics
“R” Standards for mechanicalcontraceptives
“R1” Standards for medicaldevices
“S” Standards forcosmetics
“T” Requirements (GMP) of factory premises for Ayurvedic, Siddha,
Unani drugs
“U” Manufacturing and analytical records of drugs
31. Schedulesto therules
SJTPC 31
TYPE CONTENT
“U1” Manufacturing and analytical records of cosmetics
“V” Standards for patent or proprietary medicines
“W” List of drugs marketed under generic names-
Omitted
“X” List of narcotic drugs and psychotropic substances
“Y” Requirement and guidelines on clinical trials for import and
manufacture of newdrugs
32. Penaltiesrelatedto Manufacture
OFFENCES PENALTIES
Manufacture of any spurious drugs a) 1-3 years imprisonment and
Rs.5000 fine
b) 2-6 years imprisonment &
Rs.10000 fine on subsequent
conviction
Manufacture of adulterated drugs a) 1 year imprisonment & Rs.2000
fine
b) 2 years imprisonment &
Rs.2000 fine for subsequent
conviction
Manuf. of drugs in contraventionof
the provisions
a) Imprisonment up to 3 months &
Rs.500 fine
b) Imprisonment up to 6 months
& Rs.1000 fine on subsequent
conviction
33. THETHIRD SCHEDULE
(See sub-section (6) of section 18)
CATEGORIES OF DRUGS FOR WHICH THE CENTRAL LICENSING
AUTHORITY IS EMPOWERED TO ISSUELICENCE AND PERMISSION.
1. antigens and anti-toxins;
2. blood products;
3. cytotoxic substances (anti-cancer drugs);
4. drug products containing modified living organisms;
5. fixed dose combination.
6. gene therapeutic products;
7. hormones and preparations containing hormones;
8. large volume parenterals;
9. monoclonal anti-bodies;
10. recombinant-deoxyribo nucleic acid derived drugs;
11. ribo nucleic acid derived drugs;
12. sera;
13. solution of serum proteins intended for injection;
14. stem cells and cell based drug products;
15. toxins;
16. vaccines;
34. -If the Central Government is satisfied that the use of any drug or
cosmetic is likely to involve any risk to human beings or animals
or that any drug does not have the therapeutic value claimed for it
or contains ingredients and in such quantity for which there is no
therapeutic justification and that in the public interest it is
necessary or expedient so to do then, that Government may, by
notification in the Official Gazette, prohibit the import of such
drug or cosmetic